Education
About Us
Working with TipRanks
Follow Us
IN8bio (INAB)
NASDAQ:INAB
Autologous Genetically Modified Gamma-Delta T Cells, Allogeneic Genetically Modified Gamma-Delta T Cells
Glioblastoma
Phase I/II
Active Not Recruiting
A Phase 1b / 2 Drug Resistant Immunotherapy With Activated, Gene Modified Allogeneic or Autologous γδ T Cells (DeltEx) in Combination With Maintenance Temozolomide in Subjects With Recurrent or Newly Diagnosed Glioblastoma
Dec 09, 2022
―
FAQ
What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases:
a. Preclinical testing
b. Phase 1 – Safety and dosage
c. Phase 2 – Effectiveness and side effects
d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments
e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
a. Preclinical testing
b. Phase 1 – Safety and dosage
c. Phase 2 – Effectiveness and side effects
d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments
e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does IN8bio (INAB) have in its pipeline
INAB is currently developing the following drugs: Autologous Genetically Modified Gamma-Delta T Cells, Allogeneic Genetically Modified Gamma-Delta T Cells. These drug candidates are in various stages of clinical development as the company works toward FDA approval.